Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
A permanent product-specific code would support billing, but would not guarantee payer coverage or reimbursement.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Outlook Therapeutics (OTLK) submitted an application to CMS for a permanent, product-specific J-code for LYTENAVA to support U.S. reimbursement. LYTENAVA (bevacizumab-vikg) is FDA-approved for wet age-related macular degeneration, a retinal disease. The company remains on track for a U.S. commercial launch before year-end 2026, with preparations focused on market access, reimbursement, practice readiness and supply.
A J-code is a standardized billing identifier used by government and commercial payers for physician-administered treatments. Outlook Therapeutics expects a permanent code would simplify billing, reduce administrative work and support practice adoption and patient access. The application does not guarantee code assignment. Assignment is separate from coverage and payment decisions and does not guarantee reimbursement by Medicare or other payers.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointPermanent J-code application submitted to CMS advances LYTENAVA’s U.S. reimbursement preparations.
- Moderate point. Forward-looking: it has not happened yet and may not happen.U.S. launch before year-end 2026 remains on track, Outlook Therapeutics said.
Negative
- Minor pointPermanent J-code assignment remains unconfirmed; submitting the application does not guarantee CMS approval.
- Minor point. Forward-looking: it has not happened yet and may not happen.Coverage and reimbursement are separate decisions and would not be guaranteed by J-code assignment.
Details
Market Reaction – OTLK
On Oct 1, the day this news came out, the latest delayed price for OTLK is 1.64% above the previous close. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $0.58.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Planned U.S. commercial launch
- Before the end of 2026
- Company said it remained on track
Historical Context
-
Reported the HCPCS reimbursement-code application was planned by Oct. 1, 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
hcpcs level ii regulatory
j-code regulatory
monoclonal antibody medical
vascular endothelial growth factor medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Application represents an important step in supporting reimbursement
Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026
ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure Coding System (HCPCS) Level II J-code for LYTENAVA.
The submission advances Outlook Therapeutics’ U.S. commercialization and market access strategy for LYTENAVA, the only FDA-approved ophthalmic bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The Company remains on track for a U.S. commercial launch before the end of 2026 and is focused on supporting broad market access, reimbursement and practice readiness for LYTENAVA.
“This submission represents a critical step toward securing a permanent, product-specific J-code for LYTENAVA and establishing a clear and consistent reimbursement pathway for U.S. retina practices,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “A permanent J-code would streamline billing, reduce administrative burden and support broader practice adoption and patient access. We remain focused on executing across market access, reimbursement, commercial readiness and supply ahead of our planned U.S. launch before the end of 2026.”
HCPCS Level II codes are standardized codes used to identify products, supplies and certain services for billing purposes. CMS maintains the HCPCS Level II code set and reviews applications for drugs and biologicals on a quarterly basis. Permanent J-codes are used by government and commercial payers to facilitate billing and reimbursement for physician-administered treatments.
The submission of an HCPCS Level II application does not guarantee that CMS will assign a permanent, product-specific J-code. The assignment of a J-code is separate from coverage and payment determinations and does not guarantee coverage or reimbursement by Medicare or any other payer.
About LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. In the United States, LYTENAVA (bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA. LYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of adults with wet AMD. In certain European Union Member States, LYTENAVA must receive pricing and reimbursement approval before it can be sold.
Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 monoclonal antibody specific to human vascular endothelial growth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.
Important Safety Information and Indication
LYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
Contraindications
LYTENAVA is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with a known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.
Warnings and Precautions
Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering LYTENAVA. In addition, patients should be monitored following the injection to permit early treatment should an infection occur.
Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately.
Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
Adverse Reactions
The most common adverse reactions (≥
You are encouraged to report side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Outlook Therapeutics at 1-833-999-OTLK (6855).
Please see the full U.S. Prescribing Information for LYTENAVA here.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
Forward-Looking Statements
This press release contains statements that may or are considered “forward-looking statements.” All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would,” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, express or implied discussions regarding the Company’s planned launch of LYTENAVA in the United States and other jurisdictions and the timing thereof; expectations concerning potential revenue generation from sales of LYTENAVA; expectations surrounding market adoption of LYTENAVA; expectations regarding the potential impact of LYTENAVA in the retina community; Outlook Therapeutics’ development or future revenue plans for LYTENAVA generally; and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Current Report on Form 8-K filed with the SEC on August 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.